MedTrace Logo

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

NCT00962390 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2017-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

S-equol

10mg S-equol 50mg S-equol, \& 150mg S-equol

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Ausio Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Donald Bergner, MD · Tampa Bay Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States
  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00962390 on ClinicalTrials.gov